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Patients with chronic myeloproliferative
neoplasms, including essential thrombo-
cythemia (ET), polycythemia vera (PV),
and chronic myeloid leukemia (CML), are
at increased risk of new hematologic ma-
lignancies, but their risk of nonhemato-
logic malignancies remains unknown. In
the present study, we assessed the risk of
both types of malignancies after an ET,
PV, or CML diagnosis. We linked 2 popula-
tion-based nationwide registries, the Dan-
ish National Registry of Patients, cover-
ing all Danish hospitals and the Danish
Cancer Registry, and assessed subse-
quent cancer risk in a cohort of all 7229
patients diagnosed with a chronic my-
eloproliferative neoplasm during 1977-
2008. We compared the incidence of sub-
sequent cancer in this cohort with that
expected on the basis of cancer inci-
dence in the general population (standard-
ized incidence ratio). Overall, ET, PV, and
CML patients were at increased risk of
developing both new hematologic and
nonhematologic cancers. The standard-
ized incidence ratio for developing a non-
hematologic cancer was 1.2 (95% confi-
dence interval [95% CI]): 1.0-1.4) for
patients with ET, 1.4 (95% CI: 1.3-1.5) for
patients with PV, and 1.6 (95% CI: 1.3-2.0)
for patients with CML. We conclude that
patients with chronic myeloproliferative
neoplasms are at increased risk of devel-
oping a new malignant disease. (Blood.
2011;118(25):6515-6520)
Introduction
Chronic myeloproliferative neoplasms are clonal diseases of the
BM arising from a pluripotent hematopoietic stem cell.1 Tradition-
ally, the diseases are classified based on chromosomal abnormali-
ties into the Philadelphia-chromosome–negative disorders (CMPNs)
and chronic myeloid leukemia (CML).1 The classic CMPNs are
essential thrombocythemia (ET), polycythemia vera (PV), and
primary myelofibrosis (PMF).1 Although CMPNs are considered
relatively indolent diseases, patients are at lifelong increased risk of
thrombosis, hemorrhage, and myelofibrotic or leukemic
transformation.2,3
The potential for CMPNs to evolve into more malignant and
aggressive myeloid neoplasms has been known for more than
60 years,4 but the epidemiologic evidence is limited. A recent
Italian study based on 820 PV and ET patients from a single
institution reported an increased risk for lymphoid neoplasms in
patients with CMPNs.5 The patients were followed for incident
lymphoid neoplasms through retrospective review of their clinical
records from the same institution. The investigators compared the
incidence of lymphomas among the CMPN patients with that of the
general population living in the same area as the hospital. The
resulting standardized incidence ratios (SIRs) for chronic lympho-
cytic leukemia and nonHodgkin lymphoma in CMPN patients
compared with the general population were 3.4 (95% confidence
interval [95% CI]: 1.9-6.2) and 12.4 (95% CI: 4.7-33.6),
respectively.5
Two other recent studies have investigated the association
between CMPNs and carcinomas. Rebora et al conducted a
registry-based study in Sweden focusing on the incidence of new
primary malignancies diagnosed during 1970-1995 among CML
patients compared with the general population.6 They reported
SIRs of 2.8 (95% CI: 1.3-5.1), 5.4 (95% CI: 3.2-8.5), and 1.6 (95%
CI: 1.2-2.2) for stomach cancer, nonmelanoma skin cancer, and
urogenital cancer, respectively.6 Fallah et al reported an increased
incidence of new primary cancers among patients diagnosed with
PV based on a Swedish registry study, and found SIRs above unity
for parathyroid tumors, as well as for kidney and skin cancers, after
a PV diagnosis.7
The risk of developing a subsequent cancer among patients with
different types of CMPNs compared with the general population
has not been studied previously on a large scale. In the present
study, we report the risk of developing nonhematologic and
hematologic cancers among adult patients with ET, PV, or CML
using population-based data from the Danish health care system.
Methods
Data sources and patients
The Danish National Registry of Patients (DNRP) and the Danish Cancer
Registry (DCR) provided data for this cohort study. Since 1968, all
residents of Denmark have received a unique, permanent civil registration
number, allowing unambiguous individual-level linkage among all Danish
registries. The civil registration number is a prerequisite for obtaining any
form of social benefit in Denmark, including health care.8
The DNRP, established in 1977,9 contains information on virtually all
discharges from public hospitals since 1977 and on outpatient clinic visits
since 1995. Denmark has very few private hospitals (all with no acute care).
Data recorded in the DNRP include civil registration number, dates of
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outpatient visits, hospital admission and discharge dates, and up to
20 diagnoses coded by physicians according to the World Health Organiza-
tion’s (WHO’s) International Classification of Diseases, 8th revision
(ICD-8), which covered 1977-1993 and the 10th revision (ICD-10)
thereafter. We identified all patients diagnosed with a chronic myeloprolif-
erative neoplasm during 1977-2008 by their ICD-8 or ICD-10 diagnosis
code. Because there is no specific diagnosis code for primary myelofibrosis
in the ICD-10, we created 3 cohorts of patients based on available diagnosis
codes as follows: patients with ET (ICD-8 code 287.29 or ICD-10 codes
D473 or D752), patients with PV (ICD-8 code 208.99 or ICD-10 code
D459), and patients with CML (ICD-8 code 205.19 or ICD-10 code C921).
Diagnostic coding of hematologic malignancies in the DNRP has been
reported to be valid.10 The diagnosis date was defined as the date of first
hospital admission or the first visit to an outpatient clinic with a CMPN
diagnosis code. Because CMPN is rare among children and adolescents, we
restricted the study population to patients 20 years of age or older.
Subsequent diagnoses of cancer among CMPN patients were identified
by linkage to the DCR, which has recorded all cancer diagnoses at an
individual level since 1943.11 Cancers are classified according to the
ICD-10. Registration is based on cancer diagnoses reported by hospitals,
practicing physicians, and departments of pathology and forensic medicine
at the time of original diagnosis or when changes are made to the diagnosis.
In addition, if a cancer diagnosis is made at autopsy, the DCR obtains
information through linkage to the death certificate registry. In comprehen-
sive assessments, the DCR has been found to be 95%-98% valid and
complete.11
As a first step, we used the DCR to identify all cancer diagnoses in our
3 study cohorts (patients with ET, patients with PV, and patients with
CML). To exclude other prevalent cancer diagnoses, we then eliminated
CMPN patients with a previous cancer diagnosis or a cancer diagnosis
within the first year after their ET, PV, or CML diagnosis (other than
nonmelanoma skin cancer or carcinoma in situ cervix uteri). Follow-up
status was determined through linkage to the Danish Civil Registration
System. Follow-up began on the date of first hospital admission or first visit
to an outpatient clinic resulting in a CMPN or CML diagnosis, and
continued until death, emigration, or December 31, 2008, whichever came
first. Patients diagnosed with CMPN or CML during follow-up were not
considered to have a new cancer. This study was approved by the Danish
Data Protection Agency.
Statistical analysis
We calculated the expected number of cancers after diagnosis of a CMPN or
CML using national incidence rates of cancer by age, sex, and year of
diagnosis in 1-year intervals. The number of cancers that would be expected
if patients with a CMPN had the same risk of cancer as the general Danish
population was calculated by multiplying the number of person-years of
follow-up by the incidence rates for each cancer category. The association
between a CMPN diagnosis and the risk of developing a subsequent cancer
was assessed by the SIR, the ratio of the observed number of cancers to the
expected number of cancers. We calculated 95% CIs for the estimate of the
SIR by assuming a Poisson distribution of the observed number of cancers
during the follow-up period in a specific cancer category. Exact 95% CIs
were used when the observed number of cancers was  10; otherwise, the
Byar approximation was used.12
We stratified our data by sex, age, calendar period of diagnosis, and
follow-up time in all 3 cohorts. In addition, we used chronic obstructive
pulmonary disease (COPD) as an indicator of smoking. Because blood test
results of heavy smokers can resemble those of CMPN patients, diagnostic
misclassification could occur if heavy smokers were erroneously given an
ET, PV, or CML diagnosis code. Because we lacked direct information on
smoking status, the COPD diagnosis served as a proxy measure. To estimate
the possible effect of diagnostic misclassification of ET, PV, and CML
diagnoses, we therefore stratified analyses according to whether a diagnosis
of known COPD (ICD-8 codes 490-492; ICD-10 codes J40-J44)13 had been
made before or concurrently with these diagnoses. For patients diagnosed in
1995 or later, we also stratified analyses according to hospital contact
(ie, whether patients were admitted to the hospital at any time or were
followed solely as outpatients).
Treatment options changed during the period in which these patients
were diagnosed. In Denmark, IFN- treatment was introduced in approxi-
mately 1985 and imatinib began to be used to treat CML in 2000. To
evaluate the possible effect of these new treatments on subsequent cancer
occurrence, we stratified analyses according to these 2 time points.
We present specific cancer diagnoses only for the PV cohort, and only if
5 or more cases were recorded in one of the diagnostic groups.
Results
We identified 1578 patients diagnosed with ET, 4625 patients with
PV, and 1026 patients with CML during 1977-2008 (Table 1). The
median age was 65.2 years (interquartile range [IQR] 52.6-75.3
years) among ET patients, 65.5 years (IQR 55.9-74.1 year)
among PV patients, and 59.7 years (IQR 45.2-71.0 years) among
patients with CML. In the 3 cohorts, median follow-up time was
4.0 years (IQR 1.8-7.5 years) among ET patients, 5.0 years
(IQR  2.2-9.8 years) among PV patients, and 2.4 years
(IQR 1.0-5.2 years) among patients with CML.
Table 1. Characteristics for 3 cohorts of Danish patients diagnosed with ET, PV, or CML during 1977-2008 and followed for new primary
cancers
ET patients, n (%) PV patients, n (%) CML patients, n (%)
All 1578 (100.0) 4625 (100.0) 1026 (100.0)
Women 1050 (66.5) 2017 (43.6) 446 (43.5)
Men 528 (33.5) 2608 (56.4) 580 (56.5)
Age, y
20-49 325 (20.6) 717 (15.5) 329 (32.1)
50-69 634 (40.2) 2190 (47.4) 422 (41.1)
70 619 (39.2) 1718 (37.1) 275 (26.8)
Year of diagnosis
1977-1994 233 (14.8) 2753 (59.5) 569 (55.5)
1995-2008 1345 (85.2) 1872 (40.5) 457 (44.5)
Follow-up time
Year 2 245 (15.5) 560 (12.1) 256 (25.0)
Years 3-5 550 (34.9) 1398 (30.2) 422 (41.1)
Years 6 783 (49.6) 2667 (57.7) 348 (33.9)
Outpatient contact only (for diagnoses made in 1995 and later) 834 (62.0) 1087 (58.1) 157 (34.4)
Chronic obstructive pulmonary disease 107 (7.0) 427 (9.2) 30 (2.9)
The number of patients is shown, with percentages within in each stratum in parentheses.
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In the ET cohort, 152 nonhematologic and 37 hematologic
cancers were observed during 8087 person-years of follow-up
(Table 2). In the PV cohort, 704 nonhematologic and 115 hemato-
logic cancers were observed during 31 270 person-years of fol-
low-up (Table 3). Among CML patients, the corresponding num-
bers were 75 nonhematologic and 14 hematologic cancers observed
during 3960 person-years of follow-up (Table 4).
Overall, patients in the 3 cohorts were at increased risk of
developing both new hematologic and new nonhematologic can-
cers (Tables 2-4). SIRs for developing a nonhematologic cancer
were very similar in the 3 cohorts: 1.2 (95% CI: 1.0-1.4) for ET
patients, 1.4 (95% CI: 1.3-1.5) for PV patients, and 1.6 (95% CI:
1.3-2.0) for patients with CML (Tables 2-4). The same overall
tendency was observed when results were stratified by sex; age;
year of ET, PV, or CML diagnosis (Tables 2-4); and follow-up
period (Figure 1). The SIRs for developing a hematologic cancer in
the 3 cohorts were 5.0 (95% CI: 3.6-6.9) for ET patients, 3.8 (95%
CI: 3.1-4.6) for PV patients, and 5.2 (95% CI: 2.8-8.7) for patients
with CML. After stratification by sex, age, year, and follow-up
time, the findings remained virtually unchanged. We found lower
SIRs in the latest calendar period among CML patients (Table 4).
In Table 5, the observed cancers among PV patients are
stratified by type, indicating an elevated risk of cancer of the
oropharynx, esophagus, liver, pancreas, lung, prostate, kidney,
urinary tract, eye, and skin compared with the general population.
SIRs ranged between 1.2 and 3.7. The risk of carcinoma not
specified by site was also increased, with a SIR of approximately
1.6 (Table 5). Among hematologic neoplasms, the risk was
increased mainly for myeloid neoplasms. However, the risk for
developing nonHodgkin lymphoma was also increased (SIR 1.8;
95% CI: 1.1-2.7). The SIRs for the ET and CML cohorts were very
similar to those shown in Table 5 for the PV cohort. They were
estimated with less precision, however, because of the smaller
number of patients with these diagnoses (data not shown).
We repeated all analyses stratified by gender to investigate
gender-specific effects. Overall, the SIRs for men and women were
Table 2. Observed and expected cancers and SIRs among Danish patients diagnosed with ET during 1977-2008 and followed for new
primary cancers
Person-years of
patients with ET
ET patients
with nonhematologic
cancers, n
Nonhematologic
cancers
expected, n SIR (95% CI)
ET patients with
hematologic
cancers, n
Hematologic
cancers
expected, n SIR (95% CI)
All 8087 152 125.7 1.2 (1.0-1.4) 37 7.4 5.0 (3.5-6.9)
Women 5516 89 83.3 1.1 (0.9-1.3) 23 4.5 5.1 (3.2-7.6)
Men 2571 63 42.3 1.5 (1.1-1.9) 14 2.8 5.0 (2.7-8.3)
Age at ET diagnosis, y
20-49 2280 13 12.9 1.0 (0.5-1.7) 2 0.5 3.8 (0.5-13.7)
50-69 3574 72 57.4 1.3 (1.0-1.6) 22 3.2 6.9 (4.3-10.4)
70 2234 67 55.3 1.2 (0.9-1.5) 13 3.6 3.6 (1.9-6.4)
Year of ET diagnosis
1977-1994 2198 34 29.9 1.1 (0.8-1.6) 10 1.7 5.8 (2.8-10.7)
1995-2008 5889 118 95.8 1.2 (1.0-1.5) 27 5.6 4.8 (3.2-7.0)
Follow-up time
Year 2 1455 32 22.7 1.4 (1.0-2.0) 8 1.3 6.0 (2.6-11.8)
Years 3-5 3142 60 48.9 1.2 (0.9-1.6) 15 2.9 5.2 (2.9-8.6)
Years 6 3490 60 54.1 1.1 (0.9-1.4) 14 3.1 4.5 (2.5-7.5)
Hospital contact type (from 1995 on)
Outpatient only 3350 63 53.1 1.2 (0.9-1.5) 12 3.1 3.9 (2.0-6.7)
Inpatient admission 2539 55 42.6 1.3 (1.0-1.7) 15 2.5 5.9 (3.3-9.8)
Table 3. Observed and expected cancers and SIRs among Danish patients diagnosed with PV during 1977-2008 and followed for new
primary cancers
Person-years of
patients with
PV, n
PV patients with
nonhematologic
cancers, n
Nonhematologic
cancers
expected, n SIR (95% CI)
PV patients with
hematologic
cancers, n
Hematologic
cancers
expected, n SIR (95% CI)
All 31 270 704 493.5 1.4 (1.3-1.5) 115 30.3 3.8 (3.1-4.6)
Women 12 493 278 189.7 1.5 (1.3-1.7) 47 10.6 4.4 (3.2-5.9)
Men 18 776 426 303.8 1.4 (1.3-1.5) 68 19.7 3.5 (2.7-4.4)
Age at PV diagnosis, y
20-49 8460 97 50.9 1.9 (1.6-2.3) 15 3.1 4.9 (2.7-8.1)
50-69 15 685 387 263.5 1.5 (1.3-1.6) 63 15.8 4.0 (3.1-5.1)
70 7124 220 179.0 1.2 (1.1-1.4) 37 11.5 2.3 (2.3-4.4)
Year of PV diagnosis
1977-1994 22 693 506 343.3 1.5 (1.4-1.6) 82 21.1 3.9 (3.1-4.8)
1995-2008 8577 198 150.1 1.3 (1.1-1.5) 33 9.3 3.6 (2.5-5.0)
Follow-up time
Year 2 4339 79 65.6 1.2 (1.0-1.5) 11 4.0 2.8 (1.4-5.0)
Years 3-5 10 005 212 153.9 1.4 (1.2-1.6) 35 9.4 3.7 (2.6-5.2)
Years 6 16 926 413 273.9 1.5 (1.4-1.7) 69 17 4.1 (3.2-5.1)
Hospital contact type (from 1995 on)
Outpatient only 4395 89 74.1 1.2 (1.0-1.5) 14 4.5 3.1 (1.7-5.2)
Inpatient admission 4182 109 76.1 1.4 (1.2-1.7) 19 4.7 4.0 (2.4-6.3)
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very similar (data not shown). We also examined the effect of time
elapsed between the ET, PV, or CML diagnoses and the diagnosis
of a subsequent malignancy for all specific cancer diagnoses listed
in Table 5 by stratifying according to follow-up time. No clear
trends were observed, except for myeloid leukemia, which showed
a stepwise pattern toward increasing risk with longer follow-up
time among patients with PV: SIR 8.5 (96% CI: 2.3-21.7),
SIR 14.6 (96% CI: 8.3-23.7), and SIR 18.6 (96% CI: 13.0-
25.9) for 1-2 years, 2-4 years, and 5 years of follow-up, respectively.
To evaluate the possible effects of changes in treatment options,
we also performed stratified analyses at 2 time points, 1985 and
2000. No clear changes in cancer occurrence were apparent over
this time period (data not shown). However, the SIRs for new
hematologic malignancies for CML patients may have decreased,
because the SIR for 1977-1984 was 13.4 (95% CI: 5.4-27.6) and
the SIR for 1985-2008 was 3.2 (95% CI: 1.3-6.6).
To estimate the possible effect of diagnostic misclassification of
ET, PV, and CML diagnoses, we stratified analyses according to
whether a diagnosis of COPD had been made. For nonhematologic
cancers, the observed SIRs by COPD diagnosis status were as
follows: ET without COPD 1.2 (95% CI: 1.0-1.4), ET with
COPD  1.5 (95% CI: 0.8-2.7), PV without COPD 1.4 (95%
CI: 1.3-1.5), PV with COPD 1.6 (95% CI: 1.2-2.1), CML
without COPD  1.6 (95% CI: 1.2-2.0), and CML with
COPD  3.4 (95% CI: 1.1-8.0). Among patients with PV, the SIRs
for a subsequent diagnosis of lung cancer according to COPD
status were as follows: PV without COPD 1.8 (95% CI: 1.4-2.1)
and PV with COPD 3.4 (95% CI: 2.0-5.4).
Table 4. Observed and expected cancers and SIRs among patients Danish patients diagnosed with CML during 1977-2008 and followed for
new primary cancers
Person-years of
CML patients
CML patients with
nonhematologic
cancers, n
Nonhematologic
cancers
expected, n SIR (95% CI)
CML patients with
hematologic
cancers, n
Hematologic
cancers
expected, n SIR (95% CI)
All 3960 75 46.0 1.6 (1.3-2.0) 14 2.7 5.2 (2.8-8.7)
Women 1788 27 21.4 1.3 (0.8-1.8) 5 1.1 4.7 (1.5-11.0)
Men 2172 48 24.5 2.0 (1.4-2.6) 9 1.6 5.5 (2.5-10.4)
Age at CML diagnosis, y
20-49 1772 20 7.6 2.6 (1.6-4.1) 2 0.4 5.3 (0.6-19.0)
50-69 1563 38 22.5 1.7 (1.2-2.3) 2 1.3 1.5 (0.2-5.5)
70 625 17 15.9 1.1 (0.6-1.7) 10 1.0 9.9 (4.7-18.1)
Year of CML diagnosis
1977-1994 2250 39 23.8 1.6 (1.2-2.2) 10 1.4 7.2 (3.5-13.3)
1995-2008 1710 36 22.2 1.6 (1.1-2.3) 4 1.3 3.1 (0.8-7.0)
Follow-up time
Year 2 896 14 11.0 1.3 (0.7-2.1) 6 0.7 9.2 (3.3-20.0)
Years 3-5 1561 27 18.8 1.4 (1.0-2.1) 5 1.1 4.5 (1.5-10.5)
Years 6 1503 34 16.2 2.1 (1.5-2.9) 3 0.9 3.2 (0.7-9.3)
Hospital contact type (from 1995 on)
Outpatient only 1109 15 8.6 1.7 (1.0-2.9) 0 0.5
Inpatient admission 601 21 13.5 1.6 (1.0-2.4) 4 0.8 5.0 (1.4-12.9)
Figure 1. SIR for new primary cancers according to year of follow-up for
patients with ET, PV, or CML. E indicates ET with hematologic cancer; , ET with
nonhematologic cancer; , PV with hematologic cancer; , PV with nonhematologic
cancer;, CML with hematologic cancer; and, CML with nonhematologic cancer.
Table 5. Observed and expected cancers and SIRs among Danish
patients diagnosed with PV during 1977-2008 and followed for new
primary cancers
Cancers
observed, n
Cancers
expected, n SIR (95% CI)
Oropharyngeal 14 8.9 1.6 (0.9-2.6)
Esophagus 15 6.4 2.4 (1.4-4.0)
Stomach 12 12.0 1.0 (0.5-1.7)
Colon 41 43.6 0.9 (0.7-1.3)
Rectum 21 23.0 0.9 (0.6-1.4)
Liver, primary 11 5.1 2.2 (1.1-3.9)
Gall bladder 4 3.6 1.1 (0.3-2.9)
Pancreas 21 13.9 1.5 (0.9-2.3)
Lung, primary 127 67.9 1.9 (1.6-2.2)
Breast 43 37.7 1.1 (0.8-1.5)
Cervix uteri 6 3.5 1.7 (0.6-3.8)
Corpus uteri 14 8.7 1.6 (0.9-2.7)
Ovary 4 6.7 0.6 (0.2-1.5)
Prostate 64 50.2 1.3 (1.0-1.6)
Kidney 17 9.0 1.9 (1.1-3.0)
Urinary tract 50 35.3 1.4 (1.1-1.9)
Malignant melanoma 17 10.1 1.7 (1.0-2.7)
Nonmelanoma skin cancer 146 88.5 1.7 (1.4-1.9)
Eye 3 1.0 3.1 (0.6-8.9)
Brain 10 11.4 0.9 (0.4-1.6)
Carcinoma unspecified 33 20.7 1.6 (1.1-2.2)
NonHodgkin lymphoma 20 11.4 1.8 (1.1-2.7)
Lymphoid leukemia 4 6.7 0.6 (0.2-1.5)
Multiple myeloma 8 5.3 1.5 (0.7-3.0)
Myeloid leukemia 55 3.4 16.0 (12.0-20.8)
Unspecified leukemia 17 0.5 33.1 (19.3-53.0)
Myelodysplastic syndrome 10 2.0 5.0 (2.4-9.2)
Data are stratified according to cancer type.
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Discussion
The results of the present study show that patients with ET, PV, and
CML are at increased risk of developing another malignancy
compared with the general population. This finding applies to
various solid tumors and to hematologic myeloid and lymphoid
malignancies. The cancer risk was much larger for another
hematologic malignancy (SIR 5), than for a nonhematologic
malignancy (SIR 1.5).
Our registry-based data do not provide patient-specific informa-
tion that would allow us to investigate factors that could underlie
increased cancer risk. However, cancer risk in patients with ET, PV,
and CML might be increased for several reasons. The well-known
increased risk of new hematologic myeloid malignancies such as
AML4 has been attributed to the disease itself as well as to the
treatment with cytotoxic drugs. The clonal origin of the disease and
the resulting cell proliferation predisposes patients to new genetic
abnormalities and therefore possibly to new cancers.14
Drugs previously used widely for the treatment of CMPNs
(eg, busulfan, P32, and chlorambucil) have well-established carci-
nogenic potential,15-17 especially when used in combination or
sequentially.18,19 Because the increased incidence and risk of AML
among CMPN patients treated with these drugs has been recog-
nized, their use has declined. In the past several years, the most
widely prescribed drug to treat patients with CMPNs has been
hydroxyurea (HU). The risk of leukemia attributed to HU when
used as a single cytotoxic drug treatment for CMPN is under
discussion, because studies conducted thus far have been unable to
distinguish the leukemogenic effects of the CMPN disease from
those of the treatment.15,17,18
Previously, the incidence of solid tumors among CMPN patients
compared with the general population was examined according to
specific treatment. In a secondary analysis of a randomized
controlled trial, 461 PV patients 65 years of age or more were
initially treated with P32.19 Those who were in complete remission
after 4 months were then randomized to either observation or
maintenance therapy with HU.19 When the rate of hematologic and
nonhematologic neoplasms was compared in the 2 treatment arms,
their overall rate was reported to be comparable to the general
population. However, the rate of both hematologic neoplasms and
carcinomas remained considerably higher in patients treated with
both P32 and HU.19 In another randomized trial, 293 PV patients
were randomized to either P32 or busulfan treatment. At follow-up,
no difference in rates of leukemia or carcinomas was observed.20 In an
uncontrolled study, 331 ET patients from a single hematology depart-
ment were followed for new malignancies.18 No difference in the
incidence of carcinomas was observed across different treatment arms,
including untreated patients; however, patients treated with alkylating
agents had a higher incidence of hematologic neoplasms.18
For specific cancers, associations between a PV diagnosis and
kidney cancer risk21 and HU treatment and skin cancer risk22 have
been suggested previously. Some of our results are in agreement
with the recent Swedish registry study by Fallah et al, which
reported SIRs for kidney cancer of 2.2, for nonmelanoma skin
cancer of 2.0, and for melanoma of 1.9.7 However, unlike our study,
Fallah et al did not report on increased risk of cancer of the
esophagus, liver, lung, prostate, urinary tract, or nonHodgkin
lymphoma. The cause of this discrepancy is unknown.
Some characteristics of the patients in our study may have
affected their subsequent observed cancer incidence. For example,
patients were identified using nationwide population-based regis-
tries. With this approach, no ET, PV, or CML patients were lost to
follow-up. In addition, diagnoses of ET, PV, or CML and incident
cancers were not required to be made in the same department,
hospital, or region. This may have led to a higher incidence of
cancer than observed when patients are followed in the same
department.
During the1977-1994 period, patients could be included in our
study only if they were admitted to the hospital, because registra-
tion of outpatient visits was not established in Denmark until 1995.
This may have affected cancer risk estimates at least in 2 ways.
Because patients were not identified during the earlier study period
until hospital admission, they may have been more severely
affected than patients diagnosed in the later period, possibly
influencing subsequent cancer risk. In addition, the diagnosis date
in the first study period was defined as the date of the first hospital
admission, and the inclusion of prevalent and incident CMPN cases
is therefore likely because previous outpatient visits were not
captured. This could cause selection bias toward ET, PV, or CML
patients with longer survival, who also might have a different
cancer risk. The direction of the influence of the bias introduced by
these 2 issues is not evident; however, we observed no tendency
toward higher or lower cancer risk across the time periods studied.
The low number of ET patients diagnosed during the first study
period was probably due to the definition of diagnosis date, because
ET patients are rarely admitted to the hospital. In addition, the
definition of diagnosis date in the first study period explains the
relatively short median follow-up time observed. The shorter
follow-up among CML patients was possibly influenced by the
higher mortality observed previously.23 Furthermore, we have no
information about the disease phase at which the CML diagnosis
was made. Some patients might have already been in blast crisis at
diagnosis, with the accompanying adverse prognosis.24
Another limitation is that ET, PV, and CML cases were
identified by ICD codes. Because new malignancies for patients
with a known malignant disease are not always coded, this could
lead to underestimation of the risk of a new cancer. In addition, we
cannot rule out the possibility of diagnostic misclassification of
CMPN (eg, reactive thrombocytosis25 erroneously coded as ET),
which might inflate cancer risk. To address this issue, we analyzed
SIRs for patients diagnosed with a cancer during the first 3 months
after their CMPN diagnosis. The higher SIRs observed in this
period possibly reflect some diagnostic misclassification of CMPN,
as well as increased diagnostic intensity immediately after diagno-
sis of a chronic disease (data not shown). In addition, we stratified
analyses according to COPD diagnosis status and, as expected,
observed higher lung cancer risk in patients with PV and COPD
than in patients with PV but without COPD. Nevertheless, lung
cancer risk and cancer risk in general remained above unity for PV
patients without COPD. We also found elevated cancer incidence
among CML patients, for whom misclassification of a CML
diagnosis seems unlikely because of the presence of the Philadel-
phia chromosome. Some patients with a diagnosis of ET may
instead have been in an early stage of myelofibrosis with a more
aggressive hematologic course.26 In our study, we were unable to
include a specific group of CMPN patients with myelofibrosis, and
the effect of possible diagnostic misclassification on the nonhema-
tologic cancer risk of some ET patients remains unclear.
Another factor for consideration is that most patients with
CMPNs are treated with aspirin for thrombosis prophylaxis. A
recent meta-analysis of 4 randomized trials comparing aspirin
with placebo treatment as primary prevention for vascular
events found lower colon cancer incidence and mortality among
users of low-dose aspirin compared with placebo.27 Our study
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showed no increased incidence of colorectal cancer among
CMPN patients.
The increased SIR for lymphomas in our study is in agreement
with the finding previously reported by Vannucchi et al.5 The
observed increased risk for lymphoid malignancies among CMPN
patients might be related to treatment, because immunosuppressive
drugs used for other indications have been shown previously to
increase the incidence of lymphoma.28,29
With the introduction of imatinib for the treatment of CML in
the past decade, the prognosis for this disease has changed
dramatically.30,31 This might influence cancer incidence in 2 direc-
tions. Improved survival, providing longer time-at-risk for other
health-related events, could result in higher cancer incidence
among CML patients. However, cancer incidence also may de-
crease because of less use of cytotoxic drugs, stem cell transplanta-
tion, and immunosuppressive drugs. We observed no definite
differences in cancer risk across different time periods.
In conclusion, our data suggest that risk of a new cancer is
increased in patients with myeloproliferative neoplasms.
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